Skip to main content

Tweets

New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe! Rheum Manpower Needs - More Programs https://t.co/W0mOCkyJbI https://t.co/USXTAtrE6U
Dr. John Cush @RheumNow ( View Tweet )
39 minutes 33 seconds ago
The spicy topic of turmeric in RA Curcumin has increasingly been promoted as a potential RA therapy, but data presented at #ACR22 suggests it is unable to do any better than placebo in replacing conventional rheumatoid arthritis therapies. https://t.co/C0O0DyXn34 https://t.co/kv3dw476dT
Dr. John Cush @RheumNow ( View Tweet )
15 hours 40 minutes ago
Dual target blockade may be better than one in SLE Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE).https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa
Dr. John Cush @RheumNow ( View Tweet )
16 hours 39 minutes ago
JAK inhibitors in rheumatic diseases Dr. Antoni Chan ( @synovialjoints) discusses abstracts 0510 and 0404 at #ACR22 https://t.co/7SSJITLrRT https://t.co/utjf8vlJof
Dr. John Cush @RheumNow ( View Tweet )
17 hours 40 minutes ago
AI Future of Sacroiliitis Assessment Dr. Rachel Tate ( @uptoTate) speaks with Dr. Fabian Proft about Abstract 0383 at #ACR22 Convergence. https://t.co/pfeW4iQBLq https://t.co/0lFx6CpWCx
Dr. John Cush @RheumNow ( View Tweet )
18 hours 40 minutes ago
Can I stop Methotrexate in RA? Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22. https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo
Dr. John Cush @RheumNow ( View Tweet )
19 hours 40 minutes ago
Remibrutinib in Sjogren's Syndrome Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku
Dr. John Cush @RheumNow ( View Tweet )
20 hours 39 minutes ago
Rheum Drugs & IDSA Guidelines to Treat COVID-19 https://t.co/39wTAKW83E https://t.co/ir1x66FSQ8
Dr. John Cush @RheumNow ( View Tweet )
21 hours 38 minutes ago
RECITAL Trial: RTX vs. CTX in CTD-ILD A UK study suggests the equivalent outcomes when patients with ILD associated with CTD are treated with either intravenous RTX or CTX, but with fewer adverse events with RTX. https://t.co/5yaPDaw8pZ https://t.co/kcKLkIv1bK
Dr. John Cush @RheumNow ( View Tweet )
22 hours 39 minutes ago
Recent CDC/MMWR report shows Paxlovid x 5days (including those w/ prior COVID or vaccination), had a 51% lower hospitalization rate within 30 days after diagnosis than those not prescribed Paxlovid. Use it irrespective of vaccination status https://t.co/CBc1VBSDFR https://t.co/EC8QGaFrb3
Dr. John Cush @RheumNow ( View Tweet )
23 hours 39 minutes ago
Future therapy? Nanoparticles laced with rapamycin to nanoparticle stimulate regulatory T cells to suppress autoimmune disease (tested in a mouse model). https://t.co/JHFh82siff https://t.co/Y8itPXiPho
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush @RheumNow ( View Tweet )
1 day 1 hour ago
×